UroGen Pharma Ltd.
URGN
$9.87
-$0.27-2.66%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -17.55% | -2.54% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.55% | -2.54% | |||
| Cost of Revenue | -5.71% | 0.73% | |||
| Gross Profit | -18.87% | -2.89% | |||
| SG&A Expenses | 3.58% | 16.64% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.82% | 19.59% | |||
| Operating Income | -38.99% | -51.37% | |||
| Income Before Tax | -24.63% | -47.84% | |||
| Income Tax Expenses | -85.20% | 2,810.99% | |||
| Earnings from Continuing Operations | -16.88% | -58.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -16.88% | -58.46% | |||
| EBIT | -38.99% | -51.37% | |||
| EBITDA | -39.08% | -51.57% | |||
| EPS Basic | -15.91% | -45.20% | |||
| Normalized Basic EPS | -27.64% | -31.20% | |||
| EPS Diluted | -15.91% | -45.20% | |||
| Normalized Diluted EPS | -27.64% | -31.20% | |||
| Average Basic Shares Outstanding | 0.83% | 9.12% | |||
| Average Diluted Shares Outstanding | 0.83% | 9.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||